Sai Reddy - NCCR MSE

Sai Reddy

Department of Biosystems Science and Engineering (D-BSSE), ETH Zurich

Project Leader

Publications

R. Castellanos-Rueda, R. B. Di Roberto, F. Bieberich, F. S. Schlatter, D. Palianina, O. T. P. Nguyen, E. Kapetanovic, H. Läubli, A. Hierlemann, N. Khanna, S. Reddy “speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing“ Nat. Commun. 2022. [DOI]
R. Vazquez-Lombardi, J. S. Jung, F. S. Schlatter, A. Mei, N. R. Mantuano, F. Bieberich, K. Hong, J. Kucharczyk, E. Kapetanovic, E. Aznauryan, C. R. Weber, A. Zippelius, H. Läubli, S. Reddy “High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity“ Immunity 2022. [DOI]
S. Shui, P. Gainza, L. Scheller, C. Yang, Y. Kurumida, S. Rosset, S. Georgeon, R. B. Di Roberto, R. Castellanos-Rueda, S. ReddyB. Correia “A rational blueprint for the design of chemically-controlled protein switches“ Nat. Commun. 2021. [DOI]
D. M. Mason, S. Friedensohn, C. R. Weber, C. Jordi, B. Wagner, S. M. Meng, R. A. Ehling, L. Bonati, J. Dahinden, P. Gainza, B. CorreiaS. Reddy “Optimization of Therapeutic Antibodies by Predicting Antigen Specificity from Antibody Sequence Via Deep Learning“ Nat. Biomed. Eng. 2021. [DOI]
R. B. Di Roberto, R. Castellanos-Rueda, S. Frey, D. Egli, R. Vazquez-Lombardi, E. Kapetanovic, J. Kucharczyk, S. Reddy “A Functional Screening Strategy for Engineering Chimeric Antigen Receptors with Reduced on-Target, Off-Tumor Activation“ Mol. Ther. 2020. [DOI]
T. Pesch, L. Bonati, W. Kelton, C. Parola, R. A. Ehling, L. Csepregi, D. Kitamura, S. Reddy “Molecular Design, Optimization, and Genomic Integration of Chimeric B Cell Receptors in Murine B Cells“ Front. Immunol. 2019. [DOI]
C. R. Weber, D. M. Mason, S. M. Meng, V. Greiff, W. J. Kelton, S. Reddy, C. Parola “High-throughput antibody engineering in mammalian cells by CRISPR/Cas9-mediated homology-directed mutagenesis“ Nucleic Acids Res. 2018, 46:7436-7449. [DOI]
S. Reddy “Reprogramming MHC specificity by CRISPR-Cas9-assisted cassette exchange“ Sci. Rep. 2017, 7:45775. [DOI]
M. Pogson, C. Parola, W. J. Kelton, P. Heuberger, S. Reddy “Immunogenomic engineering of a plug-and-(dis)play hybridoma platform“ Nat. Commun. 2016, 7:12535. [DOI]
Y. Cotelle, N. Chuard, S. Lascano, V. Lebrun, R. Wehlauch, N. Bohni, S. Lörcher, V. Postupalenko, S. Reddy, W. Meier, C. G. Palivan, K. Gademann, T. R. WardS. Matile “Interfacing Functional Systems“ Chimia 2016, 6:418. [DOI]
W. Kelton, T. PeschS. MatileS. Reddy “Surveying the Delivery Methods of CRISPR/Cas9 for ex vivo Mammalian Cell Engineering“ Chimia 2016, 6:439. [DOI]
M. Pogson, W. Kelton, S. Reddy “Microscale Technologies for High-Throughput Analysis of Immune Cells“ Microscale Technologies for Cell Engineering 2016:219-30. [DOI]
P. Muller, M. Kreuzaler, T. Khan, D. S. Thommen, K. Martin, K. Glatz, S. Savic, N. Harbeck, U. Nitz, O. Gluz, M. von Bergwelt-Baildon, H. Kreipe, S. Reddy, M. Christgen, A. Zippelius “Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade“ Sci. Transl. Med. 2015, 7:315ra188. [DOI]